CINECA IRIS Institutional Research Information System

BRINGHEN, Sara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.433
EU - Europa 3.493
AS - Asia 1.969
SA - Sud America 170
OC - Oceania 113
AF - Africa 55
Continente sconosciuto - Info sul continente non disponibili 1
Totale 11.234
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.192
IT - Italia 1.150
CN - Cina 837
JP - Giappone 477
SE - Svezia 368
FR - Francia 307
IE - Irlanda 264
GB - Regno Unito 260
DE - Germania 220
IN - India 200
CA - Canada 185
ES - Italia 177
NL - Olanda 113
AU - Australia 102
VN - Vietnam 95
AT - Austria 88
FI - Finlandia 88
UA - Ucraina 88
KR - Corea 77
CH - Svizzera 66
SG - Singapore 65
PL - Polonia 64
BR - Brasile 63
BE - Belgio 42
TR - Turchia 42
MX - Messico 41
HK - Hong Kong 38
GR - Grecia 37
CO - Colombia 30
HU - Ungheria 28
PE - Perù 23
PT - Portogallo 23
IL - Israele 22
RU - Federazione Russa 22
TW - Taiwan 22
DK - Danimarca 20
AR - Argentina 17
NO - Norvegia 15
SN - Senegal 15
TH - Thailandia 14
CL - Cile 13
UY - Uruguay 12
MY - Malesia 11
RO - Romania 11
HR - Croazia 10
MA - Marocco 10
NZ - Nuova Zelanda 10
PK - Pakistan 10
KW - Kuwait 9
TN - Tunisia 9
SA - Arabia Saudita 8
AE - Emirati Arabi Uniti 7
NG - Nigeria 7
ID - Indonesia 6
TT - Trinidad e Tobago 6
BO - Bolivia 5
QA - Qatar 5
AM - Armenia 4
CZ - Repubblica Ceca 4
EC - Ecuador 4
EG - Egitto 4
MT - Malta 4
PH - Filippine 4
UZ - Uzbekistan 4
AD - Andorra 3
BG - Bulgaria 3
CU - Cuba 3
DZ - Algeria 3
EE - Estonia 3
IR - Iran 3
JO - Giordania 3
KE - Kenya 3
MK - Macedonia 3
SI - Slovenia 3
BD - Bangladesh 2
IQ - Iraq 2
KY - Cayman, isole 2
LU - Lussemburgo 2
MD - Moldavia 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
VE - Venezuela 2
ZA - Sudafrica 2
CR - Costa Rica 1
ET - Etiopia 1
EU - Europa 1
GH - Ghana 1
GL - Groenlandia 1
IS - Islanda 1
JM - Giamaica 1
NP - Nepal 1
PA - Panama 1
PF - Polinesia Francese 1
PY - Paraguay 1
TJ - Tagikistan 1
Totale 11.234
Salva come PNG Salva come JPEG
Città #
Fairfield 384
Chandler 330
Redwood City 263
Dublin 251
Beijing 248
Torino 236
Ashburn 228
Florence 212
Cambridge 186
Houston 167
Woodbridge 154
Tokyo 152
Wilmington 135
Ann Arbor 127
Nyköping 127
Seattle 123
Turin 105
Dearborn 84
Vienna 79
Ottawa 77
Medford 74
Princeton 72
New York 62
Duncan 60
Pisa 60
Shanghai 60
Villeurbanne 59
London 51
Dong Ket 47
Hangzhou 46
Portland 43
Boston 40
Paris 40
Rochester 39
Guangzhou 38
Jacksonville 38
Madrid 38
Nanjing 37
Raritan 35
San Diego 35
Warsaw 34
Los Angeles 33
Chicago 31
Toronto 31
Minneapolis 30
Milan 29
Norwalk 29
Baltimore 28
Perth 27
Seoul 27
Newbury Park 26
Rome 26
Sydney 24
Chengdu 22
Hyderabad 22
Singapore 22
Amsterdam 21
Barcelona 21
Brussels 21
San Mateo 21
Philadelphia 20
Providence 20
Hebei 19
Helsinki 19
Lima 19
Brzeg 18
Breda 17
Budapest 17
Flushing 17
Osaka 17
Pittsburgh 17
San Francisco 17
Athens 16
Durham 16
St Louis 16
Xian 16
Changchun 15
Phoenix 15
São Paulo 15
Toledo 15
Wuhan 15
Boardman 14
Campi Bisenzio 14
Charlotte 14
Indianapolis 14
Atlanta 13
Changsha 13
Columbus 13
Jinan 13
Melbourne 13
Scarsdale 13
Chennai 12
Fukuoka 12
Grand Rapids 12
Honolulu 12
Montevideo 12
Mumbai 12
Pune 12
Salt Lake City 12
Santiago 12
Totale 5.765
Salva come PNG Salva come JPEG
Nome #
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study 2.353
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN) 977
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma 767
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma 539
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group 381
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension 368
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. 308
Clinical and pharmacologic features of monoclonal antibodies and checkpoint blockade therapy in multiple myeloma 279
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications 259
Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma 250
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials 250
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis 214
Determining treatment intensity in elderly patients with multiple myeloma 206
Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma 205
Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma 193
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: Results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study 184
Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma 180
How is patient care for multiple myeloma advancing? 170
Treatment of newly diagnosed elderly multiple myeloma 165
Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: A meta-analysis 140
Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, nordic and turkish myeloma study groups 139
Emerging drugs and combinations to treat multiple myeloma 139
A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients 131
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies 129
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial 128
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An International Myeloma Working Group report 123
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA) 111
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial 109
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing 108
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma 99
Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: A pooled analysis of two phase i/ii studies 90
Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma 89
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma 89
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials 88
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network 86
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials 85
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. 80
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. 77
Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score 75
Treatment of newly diagnosed elderly multiple myeloma 73
Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma Patients 73
Monoclonal antibodies to treat multiple myeloma: A dream come true 70
Maintenance Treatment and Survival in Patients With Myeloma A Systematic Review and Network Meta-analysis 68
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. 64
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. 58
Systemic virotherapy for multiple myeloma 57
Monoclonal antibodies currently in Phase II and III trials for multiple myeloma 53
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. 52
Melphalan and its role in the management of patients with multiple myeloma 50
Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. 50
Multiple myeloma patients undergoing carfilzomib: Development and validation of a risk score for cardiovascular adverse events prediction 50
Ultra-Low-Dose Whole-Body Computed Tomography Protocol Optimization for Patients With Plasma Cell Disorders: Diagnostic Accuracy and Effective Dose Analysis From a Reference Center 49
Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma 48
Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study. 47
Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy 47
Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. 46
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial 46
Cost efficiency and effectiveness of biosimilar filgrastim in autologous transplant 45
Approach to the Older Adult With Multiple Myeloma 43
Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter, open-label Phase 1/2 study 42
New treatment strategies for elderly myeloma patients 41
The role of monoclonal antibodies in the first-line treatment of transplant-ineligible patients with newly diagnosed multiple myeloma 39
Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma 34
Carfilzomib-Based Regimen and Cardiotoxicity in Multiple Myeloma: Incidence of Cardiovascular Events and Organ Damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. A Real-Life Prospective Study 4
The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review 2
Patients with Very High Risk of Cardiovascular Adverse Events during Carfilzomib Therapy: Prevention and Management of Events in a Single Center Experience 2
Totale 11.616
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.275
article - articoli 0
book - libri 0
conference - conferenze 503
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.778
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019259 0 0 0 0 0 0 0 0 0 65 121 73
2019/20201.169 49 30 44 137 89 124 116 100 205 100 97 78
2020/20212.283 74 134 164 147 206 221 195 202 232 198 202 308
2021/20222.442 174 173 149 240 176 139 269 141 127 201 300 353
2022/20232.550 151 208 184 207 178 337 183 232 256 172 246 196
2023/20241.791 176 240 161 240 191 213 169 214 60 127 0 0
Totale 11.616